Canadian biotechnology company Cardiol Therapeutics has announced topline results from its ARCHER Phase II clinical trial evaluating CardiolRx in patients with acute myocarditis.
Cardiol Therapeutics | 08/08/2025 | By Dineshwori | 207
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy